GottfriedRaffaelVon KeudellMDPhD

Director of Clinical Research in Lymphoma

Dr. Von Keudell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Loncastuximab Tesirine in WM Start of enrollment: 2022 Feb 17
Recruiting
Phase 2
Roles: Contact
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia Start of enrollment: 2023 May 02
Recruiting
Phase 2
Roles: Contact
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma Start of enrollment: 2023 Jul 18
Recruiting
Phase 2
Roles: Contact

PubMed

16 citations
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Stephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro
Blood Advances. 2023-10-24
85 citations
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2021-06-25
13 citations
The role of tazemetostat in relapsed/refractory follicular lymphoma.
Gottfried von Keudell, Gilles Salles
Therapeutic Advances in Hematology. 2021-05-27

Abstracts/Posters

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Gottfried R. von Keudell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
Gottfried R. von Keudell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Gottfried R. von Keudell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
Gottfried R. von Keudell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
Gottfried R. von Keudell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
Gottfried R. von Keudell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all